secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2026-02-23T23:59:59+00:00
Accession:  0001213900-26-019321
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio receives FDA alignment to advance XPro1595 to registrational study in Alzheimer's
--------------------------------------------------------------------------------

- FDA End-of-Phase 2 meeting yielded alignment to proceed with registrational study in biomarker-enriched early Alzheimer's patients.
- Phase 2 MINDFuL trial results and FDA feedback to be detailed in a webinar on Feb 27, 2026 at 9:30 AM ET.
- Company will seek a global partnership to maximize XPro1595's clinical and commercial potential.
- Key opinion leaders Dr. Michael Woodward and Dr. Sharon Cohen to present MINDFuL trial data and discuss pathway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390026019321/0001213900-26-019321-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390026019321/ea0277934-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-019321

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer